Brief: Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan
28/02/2024 22:35
Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS AND SATO ANNOUNCE STRATEGIC COLLABORATION AND
LICENSING
AGREEMENT FOR TOPICAL ROFLUMILAST IN JAPAN
* ARCUTIS BIOTHERAPEUTICS INC - UNDER TERMS OF AGREEMENT,
ARCUTIS
WILL RECEIVE AN UPFRONT PAYMENT OF $25 MILLION
Source text for Eikon: ID:nGNX5p5fNz
Further company coverage: ARQT.O
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4